Highlights Telix Pharmaceuticals Limited

Equities

TLX

AU000000TLX2

Market Closed - Australian S.E. Other stock markets 02:10:43 2024-05-01 am EDT			5-day change	1st Jan Change
14.67 ^AUD	-2.52%		+2.59%	+45.54%

Apr. 30	Bell Potter Downgrades Telix Pharmaceuticals to Hold from Buy, Price Target is AU$14.50	MT
Apr. 18	Jarden Adjusts Telix Pharmaceuticals Price Target to AU$13.52 from AU$13.27, Keeps at Buy	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Telix Pharmaceuticals Limited Reaffirms Revenue Guidance for the Year 2024	Apr. 17	CI
Telix Pharmaceuticals Logs Nearly $115 Million Revenue in Q1	Apr. 17	MT
Telix Pharmaceuticals Limited Announces FDA Fast Track Designation for TLX101-CDx	Apr. 15	CI
Telix Pharmaceuticals Completes Acquisition of Canadian Firm ARTMS	Apr. 11	MT
Telix Pharmaceuticals Limited completed the acquisition of ARTMS, INC.	Apr. 10	CI
Telix Pharmaceuticals Completes Acquisition of IsoTherapeutics Group	Apr. 08	MT
Telix Pharmaceuticals Limited completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million.	Apr. 08	CI
Telix Pharmaceuticals Limited Announces First Patient Dosed in Italian Named Patient ( Early Access) Program for TLX250-CDx Telix's Kidney Cancer Imaging Agent	Mar. 25	CI
Telix Pharmaceuticals to Buy Canadian Radioisotope Production Firm ARTMS	Mar. 04	MT
Telix Pharmaceuticals Limited signed an agreement to acquire ARTMS, INC. for approximately $84 million.	Mar. 03	CI
Telix Pharmaceuticals Jumps 7% on IsoTherapeutics Group Acquisition Deal	Feb. 26	MT
Telix Pharmaceuticals Limited entered into an agreement to acquire IsoTherapeutics Group, LLC for $13.6 million.	Feb. 25	CI
Telix Pharmaceuticals Posts 214% Surge in FY23 Revenue; Returns to Profit	Feb. 22	MT
Telix Pharmaceuticals Limited Provides Earnings Guidance for Full Year Revenue 2024	Feb. 22	CI
Telix Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Telix Pharmaceuticals to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform	Feb. 07	MT
Australia's Telix Pharmaceuticals jumps on potential US listing	Jan. 04	RE
Telix Pharmaceuticals Mulls US IPO	Jan. 04	MT
Telix Pharmaceuticals Files Biologics License Application with US FDA for Cancer Imaging Agent	Dec. 19	MT
Telix Pharmaceuticals Limited Submits Biologics License Application for TLX250-CDx for Imaging of Kidney Cancer	Dec. 18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Telix Pharmaceuticals Limited

Equities

TLX

AU000000TLX2

Highlights

Filters